New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy
- 1 June 2005
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 16 (suppl_2) , ii191-ii194
- https://doi.org/10.1093/annonc/mdi719
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Fluorouracil, Doxorubicin, and Cyclophosphamide Followed by Tamoxifen as Adjuvant Treatment for Patients with Stage IV Breast Cancer with No Evidence of DiseaseThe Breast Journal, 2002
- Docetaxel: Overview of an Active Drug for Breast CancerThe Oncologist, 2001
- Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?Expert Opinion on Pharmacotherapy, 2000
- Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing ChemotherapyJournal of Clinical Oncology, 1999
- Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.Journal of Clinical Oncology, 1998
- Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.Journal of Clinical Oncology, 1997
- Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimensBritish Journal of Cancer, 1993
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991